BERGEN, Norway, Feb. 17, 2021 /PRNewswire/ -- BerGenBio ASA
(OSE:BGBIO), a clinical-stage biopharmaceutical company developing
novel, selective AXL kinase inhibitors for severe unmet medical
need, is pleased to announce that its abstract has been
accepted for an oral virtual presentation at the annual Conference
on Retroviruses and Opportunistic Infections (CROI 2021), taking
place from 6-10 March 2021.
The presentation will be given by BerGenBio's collaborator,
Professor Wendy Maury, Professor of
Microbiology and Immunology at the University of Iowa (Iowa
City, USA), who will present
preclinical and mechanistic data on the potential of AXL-inhibitor
bemcentinib in the treatment of SARS-CoV-2 infection.
Registration can be accessed here:
https://www.croiconference.org/attendees/
Title: Targeting the receptor AXL by bemcentinib prevents
SARS-CoV-2 infection
Date/Session ID: To be advised closer to conference
date
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy
Featherstone,
Carina Jurs
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891
About AXL
AXL kinase is a cell membrane receptor and an essential mediator
of the biological mechanisms underlying life-threatening diseases.
In cancer, AXL suppresses the body's immune response to tumours and
drives cancer treatment failure across many indications. AXL
expression defines a very poor prognosis subgroup in most cancers.
AXL inhibitors, therefore, have potential high value at the centre
of cancer combination therapy, addressing significant unmet medical
needs and multiple high-value market opportunities. Research has
also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially
first-in-class selective AXL inhibitor in a broad phase II clinical
development programme. Ongoing clinical trials are investigating
bemcentinib in multiple solid and haematological tumours, in
combination with current and emerging therapies (including
immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular
catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity. Increase in AXL function has been linked to
key mechanisms of drug resistance and immune escape by tumour
cells, leading to aggressive metastatic cancers.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company
focused on developing transformative drugs targeting AXL as a
potential cornerstone of therapy for aggressive diseases, including
immune-evasive, therapy resistant cancers. The company's
proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad phase II
clinical development programme focused on combination and single
agent therapy in lung cancer, leukaemia and COVID-19. A
first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical
testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify
patient populations most likely to benefit from bemcentinib:
this is expected to facilitate more efficient registration trials
supporting a precision medicine-based commercialisation
strategy. BerGenBio is based in Bergen, Norway with a subsidiary in
Oxford, UK. The company is listed
on the Oslo Stock Exchange (ticker: BGBIO). For more information,
visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which
as such are not historical facts, but are based upon various
assumptions, many of which are based, in turn, upon further
assumptions. These assumptions are inherently subject to
significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and
other important factors could cause actual events to differ
materially from the expectations expressed or implied in this
announcement by such forward-looking statements.
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-to-present-preclinical-covid-19-data-at-the-conference-on-retroviruses-and-opportunistic-i,c3288304
The following files are available for download:
https://mb.cision.com/Main/15728/3288304/1374047.pdf
|
Release
|